Document is current
Any future updates will be listed below
-
Authors
Carbone, Carmine https://orcid.org/0000-0001-5168-747X
Piro, Geny
Agostini, Antonio https://orcid.org/0000-0002-6528-7140
Delfino, Pietro
De Sanctis, Francesco
Nasca, Vincenzo
Spallotta, Francesco
Sette, Claudio
Martini, Maurizio
Ugel, Stefano
Corbo, Vincenzo
Cappello, Paola https://orcid.org/0000-0002-5321-7794
Bria, Emilio
Scarpa, Aldo
Tortora, Giampaolo
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02644967 at ClinicalTrials.govnct02644967 at ClinicalTrials.govDocuments that mention this clinical trial
Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer
https://doi.org/10.1136/jitc-2021-002876
Lifting the innate immune barriers to antitumor immunity
https://doi.org/10.1136/jitc-2020-000695
nct02644967 at ClinicalTrials.govDocuments that mention this clinical trial
Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer
https://doi.org/10.1136/jitc-2021-002876
Lifting the innate immune barriers to antitumor immunity
https://doi.org/10.1136/jitc-2020-000695
nct03445533 at ClinicalTrials.govDocuments that mention this clinical trial
Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer
https://doi.org/10.1136/jitc-2021-002876
Lifting the innate immune barriers to antitumor immunity
https://doi.org/10.1136/jitc-2020-000695
nct03052205 at ClinicalTrials.govDocuments that mention this clinical trial
Phase III randomized trial evaluating tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with advanced refractory melanoma (ILLUMINATE 301).
https://doi.org/10.1200/jco.2024.42.17_suppl.lba9516
Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy
https://doi.org/10.1136/jitc-2021-003960
Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer
https://doi.org/10.1136/jitc-2021-002876
B cells imprint adoptively transferred CD8 <sup>+</sup> T cells with enhanced tumor immunity
https://doi.org/10.1136/jitc-2021-003078
Lifting the innate immune barriers to antitumor immunity
https://doi.org/10.1136/jitc-2020-000695
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)
https://doi.org/10.1200/jco.24.00727
Documents that mention this clinical trial
Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer
https://doi.org/10.1136/jitc-2021-002876
Lifting the innate immune barriers to antitumor immunity
https://doi.org/10.1136/jitc-2020-000695
-
Funding
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (12182)
Associazione Italiana per la Ricerca sul Cancro (18178)
Associazione Italiana per la Ricerca sul Cancro (18599)
Associazione Italiana per la Ricerca sul Cancro (23416)
Associazione Italiana per la Ricerca sul Cancro (23681)
Ministero della Salute (FIMCUP_J38D19000690001)
- License Information
